Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Radiation Oncology
•
Gynecologic Cancers
How do you manage patients with cervical and vulvar cancer meriting definitive chemoRT during platinum drug shortages?
Related Questions
What intracavitary brachytherapy dose (and fractionation) would you recommend for stage I vaginal cancer post-resection with positive (R1) margins?
How long of a delay are you willing to accept for vaginal cuff brachytherapy either as primary therapy or as boost?
How would you manage a POLE mutated, p53 abnormal IA myoinvasive carcinosarcoma of the endometrium with no LVSI?
What role does radiation plan in a pT1a endometrial cancer with two small metastatic foci in the abdomen found during surgery?
How do you counsel patients and partners of patients with HPV+ cancers regarding the HPV vaccine?
Can patients receive Mona Lisa or other vaginal laser therapy for vaginal atrophy after pelvic radiation?
Do you use Enterade in your patients receiving pelvic RT?
What are your top takeaways in Gynecologic Cancers from ASCO 2023?
What dose and target volume do you use for neoadjuvant chemoRT in a patient with a locally advanced uterine/endometrial cancer involving parametria, cervix, and the uterine fundus (no side wall involvement) requiring downstage to be eligible for surgery?
Do you have cut off values for neutrophil and platelet counts when doing interstitial brachytherapy for cervical cancer?
